Clozapine-related Immunodeficiency in Parkinsons Disease — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Clozapine-related Immunodeficiency in Parkinsons Disease — Stella

Recruiting

Back to Clozapine trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

France

CHU Amiens-Picardie, Salouël

Key details

Phase

Post-approval study

Sponsor

Centre Hospitalier Universitaire, Amiens

Enrollment target

~24 participants

Started

October 2024

Primary completion

September 2027

Age range

18 Years and older

Last updated November 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov